Bruton's tyrosine kinase (BTK) is an essential component of multiple signaling pathways that
regulate B cell and myeloid cell proliferation, survival, and functions, making it a promising …

Bruton's tyrosine kinase (BTK) inhibitor is a promising novel agent that has potential
efficiency in B-cell malignancies. It took approximately 20 years from target discovery to new …

Abstract Background Ibrutinib, a Bruton's tyrosine kinase inhibitor, may have clinical benefit
when administered in combination with bendamustine and rituximab and followed by …

Lymphomas can affect any organ in the body, present with a wide range of symptoms, and
be seen by primary care physicians and physicians from most specialties. They are …

Extranodal marginal zone (MZ) B-cell lymphomas of the mucosa-associated lymphoid tissue
(MALT) arise from lymphoid populations that are induced by chronic inflammation in …

Mantle cell lymphoma (MCL) is an uncommon subtype of non-Hodgkin lymphoma
previously considered to have a poor prognosis. Large gains were made in the first decade …

Ibrutinib is highly active in treating mantle cell lymphoma (MCL), an aggressive B‐cell
lymphoma. We pooled data from three ibrutinib studies to explore the impact of baseline …

Objective Ibrutinib is an irreversible inhibitor of Bruton tyrosine kinase (BTK) in B
lymphocytes as well as other kinases including interleukin‐2‐inducible T‐cell kinase (ITK) in …

The use of novel B-cell receptor signaling inhibitors results in high response rates and long
progression-free survival in patients with indolent B-cell malignancies, such as chronic …

PURPOSE Mantle cell lymphoma (MCL) is a B-cell lymphoma characterized by cyclin D1
expression. Autologous hematopoietic cell transplantation (AHCT) consolidation after …